|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-1-4
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-11716098,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-12447770,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-12456849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-14688132,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-15127339,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-16619185,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-17152018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-17492601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-18256415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-18278231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-19346378,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-19481233,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-3598227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21200420-9430521
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1935-2735
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e912
|
|
pubmed:dateRevised |
2011-7-20
|
|
pubmed:meshHeading |
pubmed-meshheading:21200420-Abdominal Pain,
pubmed-meshheading:21200420-Administration, Oral,
pubmed-meshheading:21200420-Adolescent,
pubmed-meshheading:21200420-Adult,
pubmed-meshheading:21200420-Aged,
pubmed-meshheading:21200420-Antimony,
pubmed-meshheading:21200420-Antiprotozoal Agents,
pubmed-meshheading:21200420-Brazil,
pubmed-meshheading:21200420-Child,
pubmed-meshheading:21200420-Child, Preschool,
pubmed-meshheading:21200420-Female,
pubmed-meshheading:21200420-Humans,
pubmed-meshheading:21200420-Leishmania braziliensis,
pubmed-meshheading:21200420-Leishmaniasis, Cutaneous,
pubmed-meshheading:21200420-Male,
pubmed-meshheading:21200420-Middle Aged,
pubmed-meshheading:21200420-Nausea,
pubmed-meshheading:21200420-Phosphorylcholine,
pubmed-meshheading:21200420-Prevalence,
pubmed-meshheading:21200420-Treatment Outcome,
pubmed-meshheading:21200420-Vomiting,
pubmed-meshheading:21200420-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
|
|
pubmed:affiliation |
Serviço de Imunologia, Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil. prlmachado@pq.cnpq.br
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
